RE:RE:RE:RE:H. C. Wainwright 22nd Annual Global Investment Conference stockbuphoon wrote: Hey Eric, I agree that CEO compensation is way out of whack for a tiny revenue company with major clinical trials to come but I believe that salary was $500K, cash bonus was approx $300K
and the rest is equity based of shares/options for $11M. He does not deserve equity worth this much until he executes and a reasonable $2M equity compensation would reach $11M on performance. At least it's not cash but tremendously over paid for not having accomplished much. Don't know what Thomvest is thinking.
eric40 wrote: Cut Galbraith salary and they will save 1 million a month.
What a joke, Thomvest gave him a 12 millions $ a year salary gift for grabbing the company from existing shareholders
That's how it is when they control a company.
Shareholder of Liminal have the right to vote but their vote worth nothing since Thomvest has the majority of shares.
Hopefully, the FDA will give a YES to the BLA resubmission and this will give a boost to the shareprice.
We should know within 8 days, by september 23, since the FDA has 14 days to reply after the BLA resubmission.
GLTA
If Galbraith really believes in his BS he should be happy to accept the following as a compensation package:
Cut salary/bonus from $800k to ZERO.
Cut equity/options from the current multi millions to ZERO.
Offer 1 million WARRANTS @ $33 USD redeemable till Oct 1st 2022.
If warrants expire, CEO loses his corner office.